Literature DB >> 9661797

Management of warfarin (coumarin) overdose.

T Baglin1.   

Abstract

Treatment with coumarin oral anticoagulants, such as warfarin, is effective antithrombotic therapy, but patients treated with these drugs are at significant risk of bleeding. The risk of haemorrhage increases with increasing intensity of anticoagulation and overanticoagulation is common. Reversal can be achieved by stopping the coumarin drug or administration of vitamin K, fresh frozen plasma or coagulation factor concentrates. However, there are surprisingly few studies defining the optimum dose of these products and there are no randomized studies comparing the relative benefit and risk of coagulation factor concentrates versus fresh frozen plasma. Guidelines for the management of overdose are based on level III and IV evidence and are, therefore, only grade B recommendations at best. Further studies are required to determine the most effective use of products and the dose required for safe reversal of overanticoagulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661797     DOI: 10.1016/s0268-960x(98)90020-0

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  8 in total

1.  Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.

Authors:  David L Brody; Venkatesh Aiyagari; Angela M Shackleford; Michael N Diringer
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Best practice in primary care pathology: review 8.

Authors:  W S A Smellie; K K Hampton; R Bowley; R Bowlees; S C Martin; N Shaw; J Hoffman; J P Ng; S M Mackenzie; C van Heyningen
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

Review 3.  The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures.

Authors:  Douglas L Feinstein; Belinda S Akpa; Manuela A Ayee; Anne I Boullerne; David Braun; Sergey V Brodsky; David Gidalevitz; Zane Hauck; Sergey Kalinin; Kathy Kowal; Ivan Kuzmenko; Kinga Lis; Natalia Marangoni; Michael W Martynowycz; Israel Rubinstein; Richard van Breemen; Kyle Ware; Guy Weinberg
Journal:  Ann N Y Acad Sci       Date:  2016-05-31       Impact factor: 5.691

Review 4.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

5.  Emergency reversal of antithrombotic treatment.

Authors:  Marcel Levi
Journal:  Intern Emerg Med       Date:  2008-11-12       Impact factor: 3.397

6.  Retroperitoneal haemorrhage during warfarin therapy.

Authors:  Tjun Tang; Justin Lee; Richard Dickinson
Journal:  J R Soc Med       Date:  2003-06       Impact factor: 18.000

Review 7.  Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.

Authors:  Marjolein P A Brekelmans; Kim van Ginkel; Joost G Daams; Barbara A Hutten; Saskia Middeldorp; Michiel Coppens
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

8.  Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital.

Authors:  David Bruce; Tim J C Nokes
Journal:  Crit Care       Date:  2008-08-15       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.